在乌干达人群中,Apolipoprotein E (APOE) 和阿尔茨海默病风险:一个试点病例控制研究
Kamada Lwere1,2,3, Haruna Muwonge4, Hakim Sendagire1
1Department of Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Medicine
|May 12, 2025
概括
在乌干达的一项研究中,与阿尔茨海默病 (AD) 风险相关的Apolipoprotein E (APOE) ε4基因基因在这个队列中很常见,但与AD没有显著相关. 需要进一步的研究来了解APOE在非洲人口中的作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 流行病学 流行病学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知和功能.
- Apolipoprotein E (APOE) 基因,特别是 ε4 基因基因,是已知的阿尔茨海默病风险因素,尽管其影响在全球范围内有所不同.
- 了解APOE在包括撒哈拉以南非洲在内的不同人群中的作用,对于准确的风险评估至关重要.
研究的目的:
- 调查乌干达队伍中Apolipoprotein E (APOE) 基因的流行情况.
- 确定APOE基因型与阿尔茨海默氏病 (AD) 风险在该人群中的关联.
- 探索年龄,教育和性别等因素如何改变APOE等位基因与AD之间的关系.
主要方法:
- 在乌干达进行了一项病例控制研究,其中包括45名阿尔茨海默病患者和42名健康对照.
- 用蒙特利尔认知评估 (MoCA) 评估认知功能.
- 在血液样本上使用聚合酶链反应进行APOE基因定型,并进行统计分析,包括后勤回归和通用添加模型.
主要成果:
- 在AD (42.2%) 和对照 (44.0%) 组中,e4等位基因的高度流行,超过了非洲祖先数据.
- 在对共变量进行调整后,APOE基因型或等位基因剂量与AD风险之间没有发现统计学上显著的关联.
- 阿尔茨海默病的概率随着年龄的增长而增加,特别是在低学历的e4携带者中,这表明了潜在的相互作用.
结论:
- 尽管APOE ε4等位基因的患病率很高,但在这个乌干达队列中,它与阿尔茨海默病风险的增加没有显著关联.
- 年龄和教育水平似乎影响了AD风险,可能与APOE ε4状态相互作用.
- 更大规模的,针对特定人群的研究对于阐明APOE在撒哈拉以南非洲阿尔茨海默氏症病原体中的复杂作用至关重要.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.6K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.7K
相关概念视频
01:26Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
02:23RNA Editing
8.8K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
8.8K
03:03Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K